by Xtalks
This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.
Language
🇺🇲
Publishing Since
3/24/2021
Email Addresses
0 available
Phone Numbers
0 available
April 16, 2025
In this episode, Ayesha spoke with Marc Hedrick, MD, MBA, president and CEO of Plus Therapeutics, a company focused on developing a novel class of targeted radiotherapeutics. Prior to heading Plus Therapeutics, Dr. Hedrick served in a number of executive leadership roles including president, CEO and director at Cytori Therapeutics, and president and CEO of StemSource. Dr. Hedrick is a trained general, vascular and plastic surgeon. He is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as co-director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and MBA from The Anderson School at UCLA in 2005. Tune in to hear about recent advancements and innovations in the field of radiotherapeutics, featuring some of the work Dr. Hedrick is spearheading at Plus Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured
April 9, 2025
In this episode, Ayesha spoke with Carlos Martin, MBA, chief commercial operations and revenue officer at Rocket Pharmaceuticals, a company developing gene therapy cures for rare diseases through innovative science and platforms. Carlos joined Rocket in April 2021 and established the company’s early commercial strategy and infrastructure as Chief Commercial Officer. Prior to joining Rocket, Carlos was the US Commercial Head of Advanced Accelerator Applications (AAA), a Novartis Oncology Company. His responsibilities included leading commercial strategy and new product launches as well as transforming their go-to-market model. Carlos brings in-depth background and experience globally and locally in commercial strategy and operations across a wide range of modalities and disease areas, including oncology, cardiovascular, metabolism and complex therapeutics. Carlos has a bachelor’s degree in economics from ESADE & the Polytechnic University of Barcelona, Spain and an MBA from the Thunderbird School of Global Management at Arizona State University. Tune in to hear from Carlos about the challenges and opportunities in the commercialization of gene therapies for rare diseases. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured
April 2, 2025
In this episode, Ayesha spoke with Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, a company focused on developing treatments for autoimmune diseases. Dr. Fordyce founded Vera in 2016 as an entrepreneur in residence at Kleiner Perkins Caufield and Byers, took the company public in 2021 and has advanced its lead molecule through a successful Phase II trial in IgA nephropathy. The company is on track to read out its Phase III results next quarter. Along the way, Dr. Fordyce has built a world class team of drug developers and raised over $1 billion in capital. Dr. Fordyce previously worked in clinical development leadership roles at Gilead Sciences in the 2010s, driving innovation in treatments for HIV and hepatitis. Dr. Fordyce received his BA from Harvard University and MD from Harvard Medical School, trained in Internal Medicine and served as Chief Resident at NYU Bellevue. Dr. Fordyce currently serves on the Board of Directors and as Treasurer of the Albert and Mary Lasker Foundation. Tune in to hear Dr. Fordyce discuss new innovations in therapies for autoimmune diseases like IgA nephropathy and the work he is leading at Vera Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
